OncoMatch/Clinical Trials/NCT05687747
Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma
Is NCT05687747 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Radiolabelled tracer, 68Gallium-FAPI-46 PET/MRI for hepatocellular carcinoma.
Treatment: Radiolabelled tracer, 68Gallium-FAPI-46 PET/MRI — Single centre prospective evaluation of 68Gallium(Ga68)-FAPI-46 PET/MRI in patients diagnosed with Hepatocellular Carcinoma (HCC). 68Gallium-FAPI-46 PET/MRI and standard contrasted multiphasic MRI imaging will be acquired in patients with radiological or histological diagnosis of HCC. The PET scan results will be compared to standard imaging to evaluate its role in lesion detection, characterisation and staging in patients with HCC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Demographics
Prior therapy
Cannot have received: locoregional therapy
Lab requirements
Kidney function
creatinine clearance > 30ml/min based on cockcroft gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05687747 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 99 years or younger and at least 21 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages